Ready-to-use NGAL Test™ for BN Systems has been launched by Siemens
Renal biomarker market to reach US$ 1,770 Mn by 2026
New antibodies in the area of infectious disease
New antibodies in the area of peptide hormones and infectious diseases
These Terms and Conditions (“Terms") governing the sale of products and related services ("Products”) from BioPorto Diagnostics A/S ("BIOPORTO") and Buyer. Any deviating conditions or reservations by Buyer shall only be binding if confirmed in writing by BIOPORTO. Conditions are also applicable in individual cases where Terms are not attached, but which Buyer has been made aware of the Terms.